Defence Scientific Advisory Council

Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​

Retrieved on: 
Sunday, December 10, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Partial thromboplastin time, Safety, Haemophilia, Food, HDR, Engineering, Plasma, Hematology, Bio-MEMS, Mortality, CCR5, Mouse, Multimedia, BCMS, PCR, Defence Scientific Advisory Council, World government, WFH, FIX, Committee, Availability, Investigational New Drug, World Federation of Hemophilia, Factor IX, Human services, Cas9, Bleeding, Person, Pain, Drug discovery, American Society of Hematology, DdPCR, Coronavirus Scientific Advisory Board, Society, Cell, BCM, Real-time, AAV, ELISA, Immunoglobulin G, Therapure BioPharma Inc, Pharmaceutical industry, Vaccine

“We are excited by these findings as we advance this novel BCM into clinical development to address enduring unmet medical needs for people living with hemophilia B.

Key Points: 
  • “We are excited by these findings as we advance this novel BCM into clinical development to address enduring unmet medical needs for people living with hemophilia B.
  • Many people living with hemophilia B still experience bleeding episodes, irreversible joint damage and pain with current extended-release factor IX biologic therapy.
  • “Our goal is to create a new, potentially transformative treatment option that will provide people with hemophilia B the freedom to live a normal life, free of limitations from hemophilia B.
  • The data confirmed the expected biodistribution of FIX-expressing BCMs in bone marrow tissue, where they engraft stably over time.

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Retrieved on: 
Wednesday, October 25, 2023
HCC, CSO, Conference, Magnus Christensen, Webcast, Conference call, CET, CFO, Medivir, Cancer, CMO, Patient, Defence Scientific Advisory Council, Pharmaceutical industry, Broadcasting

STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks. 

Key Points: 
  • The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks.
  • All presenters will be available to answer questions following the formal presentations.
  • To access the webcast and information about the teleconference, please click HERE !
  • The webcast will also be streamed via a link on the website: www.medivir.com/investors/calendar
    The presentation will be available on Medivir's website after the webcast.

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

Retrieved on: 
Friday, September 8, 2023
Defence Scientific Advisory Council, Associate, Vinnytsia National Medical University. N. I. Pirogov, TREM2, Pathology, Medicine, Washington University School of Medicine, Toxicology, Neurology, Microglia, Research, AD, FDA, Pharmacology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Pharmaceutical industry, Mobile phone

WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application to evaluate the Company’s oral small molecule TREM2 agonist VG-3927. The IND for VG-3927 is now open and the Company’s Phase 1 clinical trial in healthy volunteers is allowed to proceed with a partial clinical hold related to maximum exposure limit. At this time, the Company does not anticipate any delay in the current clinical development plans for VG-3927 and expects to commence dosing of the Phase 1 trial evaluating VG-3927 in healthy volunteers in October 2023.

Key Points: 
  • Per the notification, the FDA has limited the maximum exposure of VG-3927 in healthy volunteers in the planned Phase 1 clinical trial.
  • Based on preclinical studies, the Company believes that the maximum exposure limit exceeds the predicted efficacious dose of VG-3927.
  • The Company also announced today that it will host a virtual R&D event highlighting its small molecule TREM2 agonist program for AD on Wednesday, September 13, 2023, from 7:30 a.m. to 9:00 a.m.
  • To access the live webcast of this event, please register here or visit “ Events & Presentations ” in the “Investors” section of the Vigil website at www.vigilneuro.com .

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Retrieved on: 
Friday, September 1, 2023
AME Publishing Company, Lead, University, Medivir, Clifton Springs Hospital & Clinic, Cancer, DRS, Reig, Oncology, BCLC, Research, CMO, Cancer Science, Defence Scientific Advisory Council, ECMC, University of Glasgow, Liver cancer, Patient, School, Dr. Evan Alexander Erwin House, Webcast, Hospital, HCC, Lenvatinib, Disease, Pharmaceutical industry, Medical device, Beatson West of Scotland Cancer Centre

The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.

Key Points: 
  • The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.
  • He will be joined by Dr. Maria Reig, Liver Cancer Unit, Hospital Clínic BCLC group, Villarroel, Barcelona, Spain, who will discuss how HCC is different from many other tumor types and its unique treatment challenges.
  • Both Drs are investigators in the phase 1b/2a study with fostrox in combination with Lenvima and will also share their perspectives from the ongoing study.
  • The webcast will be streamed via a link on the website: www.medivir.com/investors/presentations The presentation will be available on Medivir´s website after the webcast.

Northwell Health Dr. Stacey E. Rosen Wins Prestigious Wenger Award From WomenHeart

Retrieved on: 
Tuesday, May 2, 2023
General Health, Health, Science, Research, Managed Care, Survivor, American Heart Association, Splenic infarction, Cardiovascular disease, Woman, Multimedia, Wenger, Defence Scientific Advisory Council, Organization, Rosen, MD, Social isolation, Cardiology, Credit, National Coalition of Syrian Revolutionary and Opposition Forces, Pharmaceutical industry, Nursing, Northwell Health

Northwell Health’s Senior Vice President for the Katz Institute of Women’s Health , Stacey E. Rosen, MD , has been awarded the prestigious Wenger Award for Excellence in Medical Advocacy from WomenHeart: The National Coalition for Women with Heart Disease .

Key Points: 
  • Northwell Health’s Senior Vice President for the Katz Institute of Women’s Health , Stacey E. Rosen, MD , has been awarded the prestigious Wenger Award for Excellence in Medical Advocacy from WomenHeart: The National Coalition for Women with Heart Disease .
  • The award recognizes Dr. Rosen’s significant contributions to the field of women’s heart health and patient advocacy.
  • View the full release here: https://www.businesswire.com/news/home/20230502006112/en/
    Dr. Stacey E. Rosen was awarded the Wenger Award from WomenHeart during a ceremony in Washington DC.
  • Her advocacy for women’s heart health and eliminating gender disparities in health care has inspired and improved the lives of women.

AltPep Strengthens Advisory Board with Three Leading Experts in Alzheimer’s Disease and Neurodegenerative Disorders

Retrieved on: 
Thursday, February 9, 2023
Mental Health, Health, Genetics, General Health, Research, Science, Biotechnology, MBA, Toxicity, A11, Defence Scientific Advisory Council, Amyloid, USC, Cell biology, Molecular biology, Biochemistry, University, Neurology, Associate, Vinnytsia National Medical University. N. I. Pirogov, Psychiatry, University of California, Advisory board, Pharmaceutical industry

The advisory board now consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease and other neurodegenerative disorders.

Key Points: 
  • The advisory board now consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease and other neurodegenerative disorders.
  • “We are honored to have these esteemed and accomplished scientific and clinical leaders join AltPep’s Advisory Board,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep.
  • “These individuals have each made foundational contributions to the field of neurodegenerative diseases.
  • The new advisors will join the existing advisory board members: Roger Armen, Ph.D., Sir Alan Ferscht, Ph.D., Michael Levitt, Ph.D., and Jeff Roh, M.D., MBA, M.Sc.

EnPlusOne Biosciences Expands Scientific Advisory Board

Retrieved on: 
Wednesday, February 8, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Gene editing, Middle States Commission on Higher Education, Wyss Institute, Defence Scientific Advisory Council, MIT, ALS, Young, Therapy, Dalhousie University, Harvard University, Harvard–MIT Program in Health Sciences and Technology, Biochemistry, Editorial, McGill University, Nucleic acid, Angel Award, RNA, George Church, United States Air Force Scientific Advisory Board, Harvard Medical School, Engineering, University, Wyss Institute for Biologically Inspired Engineering, Nucleic Acids Research, Oligonucleotide, Gene silencing, Outline of health sciences, Knowledge, OTS, Disease, Bachelor of Science, University of Massachusetts Chan Medical School, Angel, University of Massachusetts, Enzyme, Wyss, Doctor of Philosophy, Fine chemical, Management, Chemistry

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.
  • Dr. Watts, who was also a member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS) from 2015 to 2021, is a highly regarded scientific investigator in the oligonucleotide field.
  • Daniel Wiegand, MSChE, CEO of EnPlusOne said, “We are delighted to attract an experienced, respected researcher like Jon to our Scientific Advisory Board.
  • He serves on the Editorial Boards of Nucleic Acid Therapeutics and Nucleic Acids Research in addition to the Scientific Advisory Council of the OTS.

CCS Launches Scientific Advisory Council to Accelerate Advancements in Chronic Care Management

Retrieved on: 
Wednesday, February 1, 2023
General Health, Diabetes, Health, Managed Care, Medical Supplies, MBA, Children's Hospital Los Angeles, Pediatrics, Defence Scientific Advisory Council, American Medical Association, American Diabetes Association, Council, Diagnosis, Medtronic, Patient, Keck School of Medicine of USC, Empowerment, News, University, Conditional sentence, Fear, Medical Affairs Bureau, CCS, Associate, Medicine, Arti, Humana, CD, Pharmaceutical industry, Medical device, Dentistry, RD, MD

This news comes on the heels of the company’s recent announcement that Arti Masturzo, MD, joined CCS as its first-ever Chief Medical Officer.

Key Points: 
  • This news comes on the heels of the company’s recent announcement that Arti Masturzo, MD, joined CCS as its first-ever Chief Medical Officer.
  • Masturzo has assembled a multi-stakeholder group of experts to comprise our newly formed Scientific Advisory Council,” said Tony Vahedian, Chief Executive Officer at CCS.
  • Ding, Ms. Kulkarni, Dr. Wittlin, and Dr. Kaufman each bring unique industry expertise to the council.
  • That’s why CCS chose to assemble its Scientific Advisory Council and take a leadership role in reimagining how providers, health plans, and employers support their patients and members living with costly, debilitating chronic diseases.

New Preeclampsia Research Funded to Investigate Genetic Targets to Develop Potential Therapeutics

Retrieved on: 
Wednesday, February 8, 2023
Society, Boston Medical Center, Boston University, Cone Health Women's Hospital, Boston University Chobanian & Avedisian School of Medicine, Defence Scientific Advisory Council, Protein, Health, Pre-eclampsia, PRIME, HELLP, Division, Hospital, Infant, Cell, Fetus, Friends, Research, Family, Risk, Maternal–fetal medicine, Associate, APOL1, Apolipoprotein L1, Pregnancy, Partnership, SAN, EMPOWER, HELLP syndrome, L1, Hypertension, Visions (Grant Green album), Gynaecology, Infertility, Pharmaceutical industry, Tourism, Medicine, MD, Obstetrics

Based on the recommendations of its Scientific Advisory Council, the Preeclampsia Foundation awarded a grant totaling $99,994 USD to Wendy Kuohung, MD of Boston University.

Key Points: 
  • Based on the recommendations of its Scientific Advisory Council, the Preeclampsia Foundation awarded a grant totaling $99,994 USD to Wendy Kuohung, MD of Boston University.
  • The study is designed to potentially accelerate discovery of therapies for preeclampsia by designing placental cell lines that express variants of the APOL1 gene for drug screening.
  • "We lost our son Peter due to preeclampsia following a 29-week delivery in 2015," explained Lauren Pappas.
  • The Peter Joseph Pappas Research Grants program adds to the Preeclampsia Foundation's portfolio of research programs including the Vision Grant program for young investigators, PRIME for health services research, and EMPOWER, which helps build research capacity in low- and middle-income countries.

David K. Mineta Joins Board of Directors of Foundation for Opioid Response Efforts (FORE)

Retrieved on: 
Wednesday, February 8, 2023
Momentum, ONDCP, The arts, Defence Scientific Advisory Council, Alcohol, Special Task Force of National Anti-Drug Department – Slovakia, Community, Berkeley, Office of National Drug Control Policy, MPH, Trustee, University, California Council on Science and Technology, Opioid use disorder, San Francisco Bay Area, AARS, Senate, American Public Health Association, Social work, Associate Director of National Intelligence and Chief Information Officer, San José Unified School District, United, MSW, Management, MD, Health

New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The Foundation for Opioid Response Efforts (FORE) today announced that David K. Mineta, MSW has joined its Board of Directors.

Key Points: 
  • New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The Foundation for Opioid Response Efforts (FORE) today announced that David K. Mineta, MSW has joined its Board of Directors.
  • Prior to joining the Board of Directors of FORE, Mr. Mineta was a member of its Scientific Advisory Council.
  • He also served twice as board president for the Jefferson Union High School District Board of Trustees.
  • FORE was founded in 2018 as a private 501(c)(3) national, grant-making foundation focused on addressing the nation’s opioid crisis.